CITIUS ONCOLOGY, INC.
CTOR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CTOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTOR
Citius Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the launch and commercialization of LYMPHIR, its first FDA-approved product, while facing significant financial constraints and a going-concern risk.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for CITIUS ONCOLOGY, INC..
Similar companies
Citius Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the launch and commercialization of LYMPHIR, its first FDA-approved product, while facing significant financial constraints and a going-concern risk.
- Citius Oncology has one approved product, LYMPHIR, and is focused on its commercial launch and potential expansion into other indications [sec · filed 2025-07-14].
- As of June 30, 2026, the company reported cash & equivalents of $16.6M, total revenue of $1.5M, net income of -$8.9M, shareholders' equity of $44.9M, and total debt of $6.4M [sec].
- The company has an accumulated deficit of $53,673,344 as of March 31, 2025, and has historically relied on funding from Citius Pharma to finance operations [sec · filed 2025-07-14].
- Citius Oncology's independent registered public accounting firm has included an explanatory paragraph stating there is substantial doubt about the company's ability to continue as a going concern [sec · filed 2025-09-02].
- The company has retained Jefferies LLC as its exclusive financial advisor to evaluate strategic alternatives aimed at maximizing shareholder value [sec_mda · as of 2026-08-14].
What works
- Citius Oncology has an FDA-approved product, LYMPHIR, which provides a revenue-generating asset and a foundation for commercial operations [sec · filed 2025-07-14].
- The company has retained Jefferies LLC as its exclusive financial advisor to explore strategic alternatives, which could lead to value-enhancing transactions [sec_mda · as of 2026-08-14].
- Citius Pharma has historically provided partial funding, and the company expects to continue relying on this support, along with potential equity/debt financings and LYMPHIR sales [sec_mda · as of 2026-08-14].
What to weigh
- The company has a going-concern risk, as its independent auditor has expressed substantial doubt about its ability to continue as a going concern [sec · filed 2025-09-02].
- Citius Oncology has an accumulated deficit of $53.7M as of March 31, 2025, and has historically had minimal cash and negative working capital [sec · filed 2025-07-14].
- The company requires substantial additional funding in the near term to support commercialization and meet milestone/purchase commitments, and such funding may not be available on acceptable terms [sec · filed 2025-07-14].
- Citius Oncology has a limited operating history and has not yet demonstrated an ability to successfully commercialize LYMPHIR or achieve profitability [sec · filed 2025-07-14].
From the filings
Quoted directly from source documents.
The company's auditor has raised substantial doubt about its ability to continue as a going concern.
“our independent registered public accounting firm's report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern”
SEC filings · September 2, 2025
The company has an accumulated deficit of $53,673,344 as of March 31, 2025.
“At March 31, 2025, we had an accumulated deficit of $53,673,344.”
SEC MD&A · July 14, 2025
The company has retained Jefferies LLC to evaluate strategic alternatives.
“We also have retained Jefferies LLC as our exclusive financial advisor in evaluating strategic alternatives aimed at maximizing shareholder value.”
SEC MD&A · August 14, 2026
The company has one approved product candidate, LYMPHIR.
“We have one approved product candidate, LYMPHIR, while future product candidates, if any, resulting from our ongoing research with LYMPHIR for other possible indications, are and would be in the pre-clinical stage.”
SEC filings · July 14, 2025
Risks & what to watch (4)›
Key risks
- Going concern risk — Auditor has expressed substantial doubt about the company's ability to continue as a going concern [sec · filed 2025-09-02].
- Need for substantial funding — Company requires additional capital to meet milestone payments and purchase commitments; funding may not be available [sec · filed 2025-07-14].
- Limited commercialization experience — Company has not demonstrated ability to successfully commercialize LYMPHIR or achieve profitability [sec · filed 2025-07-14].
- Dependence on Citius Pharma — Company has historically relied on funding from Citius Pharma, which may not continue [sec_mda · as of 2026-08-14].
What to watch
- Progress in commercializing LYMPHIR and generating revenue from sales [sec_mda · as of 2026-08-14].
- Outcome of strategic alternatives evaluation by Jefferies LLC [sec_mda · as of 2026-08-14].
- Ability to secure additional financing or funding from Citius Pharma [sec_mda · as of 2026-08-14].
- Updates on the company's cash position and ability to meet milestone and purchase commitments [sec · filed 2025-07-14].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run CITIUS ONCOLOGY, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CITIUS ONCOLOGY, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
27.0 months
D/E 1.78 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$9.1M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 9,188,855 | $5.7M |
| bank of america corp /de/ | 3,835,160 | $2.4M |
| vanguard capital management llc | 1,069,648 | $663K |
| geode capital management, llc | 264,733 | $164K |
| vanguard fiduciary trust co | 121,910 | $76K |
| blackrock, inc. | 47,454 | $29K |
| northern trust corp | 45,746 | $28K |
| state street corp | 42,900 | $27K |
| arkadios wealth advisors | 11,666 | $7K |
| osaic holdings, inc. | 10,125 | $6K |
Showing top 10 of 12 institutional holders of CITIUS ONCOLOGY, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 2.9%
- Days to cover
- 4.4
- Shares short
- 655,066
- Daily short volume (Jun 16, 2026)
- 7.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CTOR short interestGovernance
Frequently asked questions
What is the AI investment thesis for CITIUS ONCOLOGY, INC.?
Citius Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the launch and commercialization of LYMPHIR, its first FDA-approved product, while facing significant financial constraints and a going-concern risk.
What is CITIUS ONCOLOGY, INC.'s lead drug candidate?
CITIUS ONCOLOGY, INC.'s most advanced tracked candidate is LYMPHIR (Approved) for Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).
Who is the CEO of CITIUS ONCOLOGY, INC.?
Mr. Leonard L. Mazur is the chief executive officer of CITIUS ONCOLOGY, INC. (CTOR).
Where is CITIUS ONCOLOGY, INC. headquartered?
CITIUS ONCOLOGY, INC. (CTOR) is headquartered in Cranford, NJ, United States.
What therapeutic areas does CITIUS ONCOLOGY, INC. focus on?
CITIUS ONCOLOGY, INC. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.